Amniotic Membrane Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product (Cryopreserved, Dehydrated), By Application (Surgical Wounds, Ophthalmology, Others), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Research And Academic Institutes), By Region & Competition, 2020-2030F

Market Overview

The Global Amniotic Membrane Market, valued at USD 3.77 Billion in 2024, is projected to experience a CAGR of 13.56% to reach USD 8.09 Billion by 2030. The amniotic membrane, the innermost layer of the placenta, is a biological tissue utilized in various medical applications due to its inherent immunomodulatory, anti-inflammatory, anti-scarring, and regenerative properties. The market for this product is primarily driven by the increasing global prevalence of chronic wounds, such as diabetic foot ulcers and burns, along with expanding applications in ophthalmology for ocular surface reconstruction. Furthermore, advancements in regenerative medicine and a growing number of surgical procedures requiring effective tissue repair solutions significantly support market expansion. For instance, according to The Primary Care Dermatology Society, in October 2023, over 500,000 individuals in the UK lived with some form of venous ulceration, illustrating the substantial patient population that could benefit from such therapies.

Despite these growth drivers, a significant challenge impeding market expansion is the comparatively high cost associated with amniotic membrane products and their related treatment protocols. This factor can limit accessibility for patients and healthcare providers, particularly in cost-sensitive healthcare systems.

Key Market Drivers

The continuous advancements in regenerative medicine and stem cell research serve as a primary catalyst for the Global Amniotic Membrane Market by expanding the understanding and applications of biological healing solutions. Ongoing research elucidates the potent anti-inflammatory, anti-scarring, and regenerative capabilities inherent in amniotic membranes, validating their therapeutic utility across a broader spectrum of conditions. These scientific breakthroughs translate into new product development and increased clinical acceptance. According to the Alliance for Regenerative Medicine, as reported by PharmaBoardroom, April 2024, '2023: A Record Year for Cell & Gene Therapy Approvals', seven cell and gene therapies received FDA approval in the U.S. in 2023, signaling robust progress in the wider regenerative therapy landscape. This regulatory success paves the way for wider adoption of biologics, including amniotic membrane products, within standard medical practice.

Concurrently, the global rise in surgical procedures demanding advanced healing solutions significantly fuels market expansion. An increasing number of operations worldwide necessitate effective post-operative care and scar reduction, areas where amniotic membranes offer distinct advantages. These procedures range from complex reconstructive surgeries to various elective interventions. According to the International Society of Aesthetic Plastic Surgery, June 2024, 'Global Survey 2023: Full Report and Press Releases', more than 15.8 million surgical procedures were performed by plastic surgeons worldwide in 2023, representing a substantial patient pool requiring optimal healing outcomes. This growing volume of surgical interventions creates a sustained demand for innovative biological grafts. The overall ecosystem supporting such therapies is also expanding, with a research article published in PubMed Central, 2024, 'Stem Cell Therapy, the Market, the Opportunities and the Threat', reporting the global increase to over 1550 companies providing services for regenerative medicine, including stem cell therapy, in 2024.

Download Free Sample Report

Key Market Challenges

The challenge is the comparatively high cost of amniotic membrane products and the related treatment protocols. This elevated cost significantly impedes the growth of the Global Amniotic Membrane Market by creating substantial barriers to accessibility for both patients and healthcare providers. When treatment costs are high, healthcare systems, particularly those operating under stringent budget constraints, face difficulties in widely adopting these advanced therapies, thereby limiting the integration of amniotic membranes into standard care pathways.

The financial strain on healthcare providers directly impacts their capacity to utilize these products. For instance, according to the American Hospital Association, in 2023, average payments for costly burn and wound services were 42.9% below costs across all payers. Such significant reimbursement shortfalls discourage hospitals and clinics from consistently offering therapies that incur substantial financial losses. Consequently, despite the proven clinical benefits of amniotic membranes, their high cost leads to restricted availability and lower utilization rates, directly hampering overall market expansion and preventing widespread patient benefit.

Key Market Trends

The increasing adoption of cryopreserved amniotic membranes represents a significant market trend, driven by their enhanced preservation characteristics that maintain biological efficacy over extended periods. Cryopreservation techniques allow for the retention of vital growth factors and extracellular matrix components, offering superior therapeutic outcomes compared to other preservation methods. A multicenter study published in MDPI in July 2023, for instance, demonstrated the effectiveness of cryopreserved amniotic membrane allograft applications in wound healing, achieving approximately 69% healing capacity for nonhealing wounds, significantly higher than the 21% observed with standard of care treatments. This robust clinical performance is a primary catalyst for their expanding use. The American Association of Tissue Banks, a key industrial association, plays a crucial role in ensuring the quality and safety of such products, with over 120 accredited tissue establishments globally committed to processing and distributing donated human tissue, which forms the fundamental infrastructure for cryopreserved allografts.

Concurrently, the rising utilization of amniotic membranes in outpatient and ambulatory care settings is a transformative trend reshaping market access and delivery models. This shift is largely attributable to the convenience, cost-effectiveness, and minimally invasive nature of applying these therapies in non-hospital environments. Outpatient procedures for ocular surface diseases, in particular, are seeing increased adoption of amniotic membranes. According to the American Academy of Ophthalmology in 2024, an estimated 3.2 million women and 1.68 million men aged 50 and over are affected by dry eye syndrome, a widespread condition frequently managed in outpatient clinics where amniotic membrane treatments prove beneficial. Further highlighting this trend, research from Stanford University, reported in August 2025, analyzed Medicare data and indicated that by 2020, 44% of claims for ocular amniotic membrane grafts for dry eye conditions originated from optometrists, reflecting a substantial move toward outpatient care delivery.

Segmental Insights

The Cryopreserved segment is identified as the fastest-growing within the Global Amniotic Membrane Market, primarily due to its superior efficacy and preservation of critical biological properties. Cryopreservation techniques effectively maintain the structural integrity and essential growth factors, cytokines, and extracellular matrix components inherent in the amniotic membrane, which are vital for tissue repair and regeneration. This preservation method ensures the retention of potent anti-inflammatory, anti-scarring, and regenerative healing capabilities, making cryopreserved membranes highly effective for various medical applications, including ophthalmology and wound care. The ability of these products to promote faster healing and reduce inflammation significantly contributes to their increasing adoption by healthcare professionals. Moreover, some cryopreserved amniotic membrane products have received specific designations from the U. S. Food and Drug Administration (FDA) for their therapeutic claims, further bolstering market confidence and driving segment growth.

Regional Insights

North America holds a leading position in the Global Amniotic Membrane Market due to its robust healthcare infrastructure and the significant presence of key industry participants. A strong emphasis on regenerative medicine and the swift adoption of advanced therapeutic technologies further strengthen the region's dominance. Favorable regulatory frameworks, including clear guidelines from bodies like the U.S. Food and Drug Administration (FDA) and Health Canada, coupled with supportive reimbursement policies, encourage broader clinical utilization and investment in research and development. This environment fosters innovation and facilitates the integration of amniotic membrane products into routine medical practice.

Recent Developments

• In October 2025, Integra LifeSciences Corporation formed a strategic partnership with a major hospital network. This collaboration focuses on the co-development and distribution of innovative amniotic membrane products. The initiative is specifically aimed at expanding solutions for ophthalmic and orthopedic applications, which are key segments within the Global Amniotic Membrane Market. This alliance is anticipated to enhance patient accessibility to advanced regenerative treatments by combining Integra LifeSciences' product development expertise with the hospital network's clinical reach and insights.

• In July 2024, MiMedx Group, Inc. announced the publication of a significant peer-reviewed study in Nature – Scientific Reports. The research elucidated a potential mechanism through which placental-based allografts can modulate scarring and fibrosis during surgical procedures. The study rigorously evaluated both dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM) derived from placental tissue. Findings indicated that these amniotic membranes demonstrated an ability to regulate collagen production, deposition, and maturation, suggesting their role in interrupting pathological fibrosis and potentially restoring tissue homeostasis.

• In June 2024, BioTissue unveiled CAM360 AmnioGraft, a new cryopreserved amniotic membrane solution specifically designed for patients with ocular surface diseases. This product, suitable for mild to moderate dry eye disease and other conditions, is shelf-stable and hydrated, eliminating the need for refrigeration. Its innovative CryoTek and SteriTek preservation methods help retain critical components found in fresh amniotic tissue, which contribute to its therapeutic benefits. CAM360 AmnioGraft is also a ringless membrane with adhesive properties, designed to enhance patient comfort and ensure proper placement under a bandage contact lens, thereby simplifying application for eye care professionals.

• In February 2024, RTI Surgical, a global surgical implant company, completed its acquisition of Cook Biotech, a recognized innovator in biologic tissue engineering. This strategic move was intended to expand RTI Surgical's product portfolio by integrating Cook Biotech's advanced regenerative medicine solutions. The acquisition effectively positioned RTI Surgical as a comprehensive entity in the regenerative medicine sector, offering a broad range of both allograft and xenograft biomaterials. This consolidation is expected to bolster the company's capabilities in providing advanced biologic solutions for various surgical procedures within the Global Amniotic Membrane Market.

Key Market Players

• Alliqua BioMedical Inc.
• Amnio Technology LLC
• Applied Biologics
• Human Regenerative Technologies, LLC
• Integra LifeSciences Corporation
• MiMedx Group Inc.
• Skye Biologics Holdings, LLC
• BioTissue, Inc.
• Organogenesis, Inc.

Report Scope:

In this report, the Global Amniotic Membrane Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Amniotic Membrane Market, By Product:

o   Cryopreserved

o   Dehydrated

• Amniotic Membrane Market, By Application:

o   Surgical Wounds

o   Ophthalmology

o   Others

• Amniotic Membrane Market, By End-User:

o   Hospitals

o   Ambulatory Surgical Centers (ASCs)

o   Specialty Clinics

o   Research And Academic Institutes

• Amniotic Membrane Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Amniotic Membrane Market.

Available Customizations:

Global Amniotic Membrane Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Amniotic Membrane Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]